{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:49:56Z","timestamp":1792622996053,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Denosumab, a monoclonal antibody targeting RANKL, is widely used for the treatment of osteoporosis. In addition to its skeletal benefits, emerging evidence suggests that denosumab may also exert positive effects on muscle health by modulating inflammation, myostatin expression, and insulin sensitivity through the RANK\/RANKL\/OPG pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To systematically review the available literature on the effects of denosumab on muscle-related outcomes, including muscle strength, muscle mass, physical performance, and fall risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with PRISMA guidelines. Databases including PubMed, Embase, and Cochrane Library were searched through May 2025 for studies evaluating the impact of denosumab on muscle health in human subjects. Outcomes of interest included grip strength, lean muscle mass, gait speed, fall incidence, and physical performance tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven studies met the inclusion criteria, including randomized trials and observational cohorts. Most reported favorable outcomes for denosumab compared to bisphosphonates or placebo, particularly in grip strength and physical performance. Preclinical studies further support the biological role of RANKL in muscle dysfunction. However, one recent randomized controlled trial in older adults residing in long-term care settings found no significant effect on muscle outcomes, highlighting inconsistencies in the evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Denosumab shows potential for improving muscle-related outcomes in older adults, particularly those with osteosarcopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence is heterogeneous and inconclusive. Further high-quality randomized trials are needed to clarify the effects of denosumab on muscle health and its possible role in sarcopenia prevention and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-025-03285-0","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:58:16Z","timestamp":1767949096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beyond bone effects: the role of denosumab in muscle Health \u2013 A systematic review"],"prefix":"10.1007","volume":"38","author":[{"given":"Chiara","family":"Ceolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ziliotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Virgilio","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bertocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"De Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"1","key":"3285_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/MCO.0000000000000230","volume":"19","author":"J-Y Reginster","year":"2016","unstructured":"Reginster J-Y, Beaudart C, Buckinx F, Bruy\u00e8re O (2016) Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care 19(1):31\u201336. https:\/\/doi.org\/10.1097\/MCO.0000000000000230","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"3285_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02425-z","author":"GP Arcidiacono","year":"2024","unstructured":"Arcidiacono GP et al (2024) Taking care of inpatients with fragility hip fractures: the hip-padua osteosarcopenia (Hip-POS) fracture liaison service model. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-024-02425-z","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"3285_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40520-023-02378-y","volume":"35","author":"C Ceolin","year":"2023","unstructured":"Ceolin C et al (2023) Functional autonomy and 12-month mortality in older adults with proximal femoral fractures in an orthogeriatric setting: risk factors and gender differences. Aging Clin Exp Res 35(5):1063\u20131071. https:\/\/doi.org\/10.1007\/s40520-023-02378-y","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"3285_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169","journal-title":"Age Ageing"},{"issue":"1","key":"3285_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04085-9","volume":"23","author":"T Huang","year":"2023","unstructured":"Huang T et al (2023) Prevalence and risk factors of osteosarcopenia: a systematic review and meta-analysis. BMC Geriatr 23(1):369. https:\/\/doi.org\/10.1186\/s12877-023-04085-9","journal-title":"BMC Geriatr"},{"issue":"1","key":"3285_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jcsm.13392","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S et al (2024) Global epidemiological features and impact of osteosarcopenia: a comprehensive meta-analysis and systematic review. J Cachexia Sarcopenia Muscle 15(1):8\u201320. https:\/\/doi.org\/10.1002\/jcsm.13392","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3285_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084300","author":"A Najm","year":"2024","unstructured":"Najm A, Niculescu A-G, Grumezescu AM, Beuran M (2024) Emerging therapeutic strategies in sarcopenia: an updated review on pathogenesis and treatment advances. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25084300","journal-title":"Int J Mol Sci"},{"key":"3285_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192422","author":"K Sakuma","year":"2023","unstructured":"Sakuma K, Hamada K, Yamaguchi A, Aoi W (2023) Current nutritional and pharmacological approaches for attenuating sarcopenia. Cells. https:\/\/doi.org\/10.3390\/cells12192422","journal-title":"Cells"},{"key":"3285_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/nu16193271","author":"S Cacciatore","year":"2024","unstructured":"Cacciatore S et al (2024) Emerging targets and treatments for sarcopenia: a narrative review. Nutrients. https:\/\/doi.org\/10.3390\/nu16193271","journal-title":"Nutrients"},{"issue":"38","key":"3285_CR10","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.2174\/1381612820666140316132246","volume":"20","author":"V Zanandrea","year":"2014","unstructured":"Zanandrea V, Giua R, Costanzo L, Vellas B, Zamboni M, Cesari M (2014) Interventions against sarcopenia in older persons. Curr Pharm Des 20(38):5983\u20136006. https:\/\/doi.org\/10.2174\/1381612820666140316132246","journal-title":"Curr Pharm Des"},{"issue":"13","key":"3285_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2174\/1381612821666150130122032","volume":"21","author":"AM Martone","year":"2015","unstructured":"Martone AM et al (2015) Treating sarcopenia in older and oldest old. Curr Pharm Des 21(13):1715\u20131722. https:\/\/doi.org\/10.2174\/1381612821666150130122032","journal-title":"Curr Pharm Des"},{"issue":"12","key":"3285_CR12","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1111\/jgs.16165","volume":"67","author":"S Phu","year":"2019","unstructured":"Phu S, Hassan E. Bani, Vogrin S, Kirk B, Duque G (2019) Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults. J Am Geriatr Soc 67(12):2660\u20132661. https:\/\/doi.org\/10.1111\/jgs.16165","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"3285_CR13","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1007\/s10067-021-05757-w","volume":"40","author":"Y El Miedany","year":"2021","unstructured":"El Miedany Y et al (2021) Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? Clin Rheumatol 40(10):4225\u20134232. https:\/\/doi.org\/10.1007\/s10067-021-05757-w","journal-title":"Clin Rheumatol"},{"issue":"8","key":"3285_CR14","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","volume":"129","author":"N Bonnet","year":"2019","unstructured":"Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S (2019) RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest 129(8):3214\u20133223. https:\/\/doi.org\/10.1172\/JCI125915","journal-title":"J Clin Invest"},{"issue":"15","key":"3285_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"3285_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.612506","volume":"8","author":"M Pizzonia","year":"2021","unstructured":"Pizzonia M et al (2021) Osteosarcopenia in very old age adults after hip fracture: a real-world therapeutic standpoint. Front. Med. 8:612506. https:\/\/doi.org\/10.3389\/fmed.2021.612506","journal-title":"Front. Med."},{"issue":"10","key":"3285_CR17","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00198-022-06470-3","volume":"33","author":"T Rupp","year":"2022","unstructured":"Rupp T et al (2022) Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporos Int 33(10):2177\u20132184. https:\/\/doi.org\/10.1007\/s00198-022-06470-3","journal-title":"Osteoporos Int"},{"issue":"8","key":"3285_CR18","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11739-024-03725-1","volume":"19","author":"A Casabella","year":"2024","unstructured":"Casabella A et al (2024) Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK\/RANKL system\u2019s inhibitor denosumab vs. bisphosphonates. Intern Emerg Med 19(8):2193\u20132199. https:\/\/doi.org\/10.1007\/s11739-024-03725-1","journal-title":"Intern Emerg Med"},{"issue":"6","key":"3285_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3972","volume":"35","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P et al (2020) A pooled analysis of fall incidence from placebo-controlled trials of denosumab. J Bone Miner Res 35(6):1014\u20131021. https:\/\/doi.org\/10.1002\/jbmr.3972","journal-title":"J Bone Miner Res"},{"issue":"4","key":"3285_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12603-014-0543-z","volume":"19","author":"YR Huo","year":"2015","unstructured":"Huo YR et al (2015) Comprehensive nutritional status in sarco-osteoporotic older fallers. J Nutr Health Aging 19(4):474\u2013480. https:\/\/doi.org\/10.1007\/s12603-014-0543-z","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"3285_CR21","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","volume":"97","author":"J Li","year":"2000","unstructured":"Li J et al (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97(4):1566\u20131571. https:\/\/doi.org\/10.1073\/pnas.97.4.1566","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3285_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","volume":"39","author":"H Takayanagi","year":"2021","unstructured":"Takayanagi H (2021) RANKL as the master regulator of osteoclast differentiation. J Bone Miner Metab 39(1):13\u201318. https:\/\/doi.org\/10.1007\/s00774-020-01191-1","journal-title":"J Bone Miner Metab"},{"issue":"8","key":"3285_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"3285_CR24","doi-asserted-by":"publisher","unstructured":"Pin F et al (2022) RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice., J. bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 37, no. 3, pp. 381\u2013396, Mar. https:\/\/doi.org\/10.1002\/jbmr.4480","DOI":"10.1002\/jbmr.4480"},{"issue":"3","key":"3285_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/hmg\/ddz312","volume":"29","author":"D Hamoudi","year":"2020","unstructured":"Hamoudi D et al (2020) Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice. Hum Mol Genet 29(3):483\u2013494. https:\/\/doi.org\/10.1093\/hmg\/ddz312","journal-title":"Hum Mol Genet"},{"key":"3285_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtm.2021.03.022","volume":"21","author":"Z Bouredji","year":"2021","unstructured":"Bouredji Z, Hamoudi D, Marcadet L, Argaw A, Frenette J (2021) Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair. Mol Ther Methods Clin Dev 21:559\u2013573. https:\/\/doi.org\/10.1016\/j.omtm.2021.03.022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"3285_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0533-1","volume":"6","author":"SS Dufresne","year":"2018","unstructured":"Dufresne SS et al (2018) Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. Acta Neuropathol Commun 6(1):31. https:\/\/doi.org\/10.1186\/s40478-018-0533-1","journal-title":"Acta Neuropathol Commun"},{"key":"3285_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.12659\/AJCR.882771","volume":"13","author":"SS Lefkowitz","year":"2012","unstructured":"Lefkowitz SS, Lefkowitz DL, Kethley J (2012) Treatment of facioscapulohumeral muscular dystrophy with denosumab. Am J Case Rep 13:66\u201368. https:\/\/doi.org\/10.12659\/AJCR.882771","journal-title":"Am J Case Rep"},{"key":"3285_CR29","doi-asserted-by":"publisher","first-page":"117552","DOI":"10.1016\/j.bone.2025.117552","volume":"198","author":"NS Haeri","year":"2025","unstructured":"Haeri NS, Perera S, Greenspan SL (2025) Impact of denosumab on muscle health in older adults in long-term care. Bone 198:117552. https:\/\/doi.org\/10.1016\/j.bone.2025.117552","journal-title":"Bone"},{"key":"3285_CR30","doi-asserted-by":"crossref","unstructured":"AIFA (2015) Nota 79, pp. 4\u201312","DOI":"10.1177\/1741134315618535"},{"issue":"10","key":"3285_CR31","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52(10):1031\u20131041. https:\/\/doi.org\/10.1177\/1060028018768808","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3285_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4235\/agmr.22.0139","volume":"27","author":"IGPS Aryana","year":"2023","unstructured":"Aryana IGPS, Rini SS, Setiati S (2023) Denosumab\u2019s therapeutic effect for future osteosarcopenia therapy\u202f: a systematic review and meta-analysis. Ann Geriatr Med Res 27(1):32\u201341. https:\/\/doi.org\/10.4235\/agmr.22.0139","journal-title":"Ann Geriatr Med Res"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03285-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:24:11Z","timestamp":1768919051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03285-0","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Ceolin is a member of the Editorial Board of\n                      Aging Clinical and Experimental Research\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"46"}}